Pulmonary fibrosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:17:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pulmonary fibrosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long‑term Safety and Tolerability of Admilparant in Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ Tue, 23 Jun 2026 04:12:48 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ The study focuses on people with lung scarring that gets worse over time, called Progressive pulmonary fibrosis, and a form where the cause is unknown, known as Idiopathic pulmonary fibrosis. The medicine being tested is an oral tablet named Admilparant, which blocks a protein that contributes to the disease.

The purpose is to determine whether long‑term use of Admilparant is safe and does not lead to serious side effects.

Participants will take one tablet each day for several years while doctors perform regular check‑ups. At each visit routine blood work, a quick heart test called an ECG that records the heart’s electrical activity, and measurements of blood pressure and heart rate are done. The study records any side effects, changes in test results, or reasons to stop the medication, and follows each person from the start until the study ends.

]]> Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-18f-alf-fapi-74-for-identifying-fibrosis-and-inflammation-in-patients-with-progressive-pulmonary-fibrosis-2/ Fri, 05 Jun 2026 10:51:53 +0000 https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-18f-alf-fapi-74-for-identifying-fibrosis-and-inflammation-in-patients-with-progressive-pulmonary-fibrosis-2/ This clinical trial is focused on studying Progressive Pulmonary Fibrosis (PPF), a lung disease where the tissue in the lungs becomes thick and stiff, making it difficult to breathe. The study will use a special imaging technique called PET/CT with a substance known as [18F]-AlF-FAPI-74. This substance is injected into the body and helps to highlight areas of the lungs that are affected by fibrosis or inflammation, which are two different types of tissue changes that can occur in PPF.

The purpose of the study is to see if this imaging method can help doctors tell the difference between areas of the lung that are mostly fibrotic (thickened tissue) and those that are mostly inflamed (swollen tissue). This could help in understanding the disease better and in deciding the best treatment approach for patients with PPF. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Participants in the study will undergo the PET/CT imaging process, which involves lying still while a machine takes detailed pictures of the inside of the body. The study will track how the [18F]-AlF-FAPI-74 substance behaves in the body and how it highlights the different types of lung tissue. The study aims to gather information over a period of time to see how well this imaging technique works in identifying the different patterns of lung changes in PPF.

]]> A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bi-1015550-in-people-with-lung-abnormalities-and-a-family-history-of-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:09:15 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bi-1015550-in-people-with-lung-abnormalities-and-a-family-history-of-pulmonary-fibrosis/ This study investigates the effect of nerandomilast in reducing the risk of worsening lung abnormalities in individuals with interstitial lung diseases and a family history of pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes thick and scarred over time. The study also focuses on people with interstitial lung abnormalities, which are early signs of changes in the lungs. Familial pulmonary fibrosis refers to this lung scarring when it runs in a family.

Participants in the study will be given either nerandomilast, which is an oral medication, or a placebo. The purpose of the study is to determine if the medication can help slow down the progression of these lung changes. During the study, researchers will monitor how the lungs function and look for any changes in the lung tissue using high-resolution computed tomography, which is a detailed type of CT scan used to see the lungs more clearly.

The study is designed to last for 24 months. During this time, the effectiveness and safety of the treatment will be observed. Researchers will monitor lung function through various measures, including the amount of air the lungs can hold and how well oxygen moves from the lungs into the blood.

]]> A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-admilparant-in-patients-with-progressive-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:09:00 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-admilparant-in-patients-with-progressive-pulmonary-fibrosis/ This study aims to evaluate the efficacy and safety of a study drug known as BMS-986278, also referred to as admilparant, in individuals living with Progressive Pulmonary Fibrosis. Progressive Pulmonary Fibrosis is a condition where the lung tissue becomes thick and scarred over time, making it harder to breathe. The treatment being tested is an LPA1 antagonist, which is a type of medication designed to block specific signals in the body that may contribute to the scarring of the lungs. This medication is taken as an oral use film-coated tablet.

Participants in the study will be randomly assigned to receive either the active medication or a placebo. The study is double-blind, meaning that neither the participants nor the researchers will know which specific treatment is being administered during the course of the trial. The process involves monitoring changes in Forced Vital Capacity, which is a measurement of the total amount of air a person can exhale from their lungs after taking a deep breath. The study will track these changes and other health factors over a period of time to see how the medication affects the progression of the disease.

]]> Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis https://clinicaltrials.eu/trial/long-term-safety-study-of-inhaled-pirfenidone-for-patients-with-progressive-or-idiopathic-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:05:07 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-inhaled-pirfenidone-for-patients-with-progressive-or-idiopathic-pulmonary-fibrosis/ This clinical trial is focused on studying two lung diseases: Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF). These are conditions where the lungs become scarred over time, making it difficult to breathe. The treatment being tested is a medication called Pirfenidone Solution for Inhalation, which is designed to be inhaled using a device known as the eFlow Nebulizer System. This study aims to understand the long-term safety and how well patients can tolerate this inhaled medication.

Participants in this study will have previously taken part in other studies involving inhaled antifibrotic treatments. The study will observe participants over an extended period to monitor any side effects or changes in their condition. The goal is to gather information on how the treatment affects the progression of the lung diseases and to ensure it is safe for long-term use.

Throughout the study, researchers will keep track of any new health issues that arise, changes in lung function, and any serious health events. This information will help determine if the inhaled medication is a viable long-term treatment option for people with PPF and IPF. Participants will use the inhalation device as instructed and attend regular study visits to provide feedback and undergo health assessments.

]]> Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-on-the-effects-of-inhaled-treprostinil-for-patients-with-progressive-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:02:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-inhaled-treprostinil-for-patients-with-progressive-pulmonary-fibrosis/ This clinical trial is focused on studying a lung disease called Progressive Pulmonary Fibrosis (PPF). PPF is a condition where the lungs become scarred over time, making it difficult to breathe. The study will test a treatment called Treprostinil, which is given as a solution to be inhaled using a nebulizer. A nebulizer is a device that turns liquid medicine into a mist, making it easier to breathe in. The study will compare the effects of Treprostinil with a placebo, which looks like the real treatment but does not contain the active drug.

The purpose of the study is to see if inhaled Treprostinil can improve lung function in people with PPF over a period of 52 weeks, which is about one year. Participants will be randomly assigned to receive either Treprostinil or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. Throughout the study, participants will have regular check-ups to monitor their lung function and overall health.

Participants will be observed for any changes in their condition, including lung function and symptoms, as well as any side effects from the treatment. The study will also look at how long it takes for any worsening of the disease to occur and will track overall survival rates. The goal is to determine if Treprostinil can help slow down the progression of PPF and improve the quality of life for those affected by this condition.

]]> Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-of-inhaled-pirfenidone-for-patients-with-progressive-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:00:26 +0000 https://clinicaltrials.eu/trial/study-of-inhaled-pirfenidone-for-patients-with-progressive-pulmonary-fibrosis/ This clinical trial is focused on studying a lung condition known as Progressive Pulmonary Fibrosis (PPF). PPF is a disease where the lungs become scarred over time, making it difficult to breathe. The study will evaluate a treatment called Pirfenidone Solution for Inhalation, also referred to as AP01. This treatment is administered through a device called the eFlow Nebuliser System, which helps deliver the medication directly into the lungs in the form of a mist.

The purpose of the study is to assess the safety and effectiveness of AP01 in people with PPF. Participants in the study will be randomly assigned to receive either the AP01 treatment or a placebo, which looks like the treatment but does not contain the active medication. The study will last for 52 weeks, during which participants will have regular check-ups to monitor their lung function and overall health.

Throughout the study, the main focus will be on changes in lung function, specifically measuring something called forced vital capacity (FVC), which is a way to assess how well the lungs are working. Additionally, the study will look at the quality of life of participants and any changes in lung scarring using a special imaging method called high-resolution computed tomography (HRCT). The goal is to understand how AP01 might help improve breathing and slow down the progression of lung scarring in people with PPF.

]]> Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-on-bi-1839100-for-reducing-cough-in-patients-with-idiopathic-or-progressive-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:00:16 +0000 https://clinicaltrials.eu/trial/study-on-bi-1839100-for-reducing-cough-in-patients-with-idiopathic-or-progressive-pulmonary-fibrosis/ This clinical trial is focused on studying two lung diseases: Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). These conditions are characterized by scarring of the lung tissue, which can lead to a persistent cough and difficulty breathing. The trial will test a new treatment called BI 1839100, which is taken as a film-coated tablet. The purpose of the study is to see if this medication can help reduce cough in people with these lung conditions.

Participants in the study will be randomly assigned to receive either the BI 1839100 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for 12 weeks, during which the participants will take the medication orally. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

The main goal is to observe any changes in the frequency of coughing over the course of the study. Researchers will also look at how different doses of BI 1839100 affect cough frequency and assess the safety of the medication. This study aims to provide valuable information on whether BI 1839100 can be an effective treatment for reducing cough in patients with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis.

]]> Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-18f-alf-fapi-74-for-identifying-fibrosis-and-inflammation-in-patients-with-progressive-pulmonary-fibrosis/ Wed, 29 Apr 2026 14:59:14 +0000 https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-18f-alf-fapi-74-for-identifying-fibrosis-and-inflammation-in-patients-with-progressive-pulmonary-fibrosis/ This clinical trial is focused on studying a lung condition known as Progressive Pulmonary Fibrosis (PPF). This disease involves the thickening and scarring of lung tissue, which can make breathing difficult. The study will use a special imaging technique called PET/CT to help distinguish between two types of lung tissue changes: active fibrosis, which is the formation of scar tissue, and inflammation, which is the body’s response to injury or infection.

The treatment being studied involves a substance called [18F]-AlF-FAPI-74, which is a solution for injection. This substance is used in the imaging process to help identify the different types of tissue changes in the lungs. The purpose of the study is to see if this imaging method can effectively tell the difference between active fibrosis and inflammation in patients with PPF.

Participants in the study will receive an injection of [18F]-AlF-FAPI-74 and then undergo a PET/CT scan. This scan will help researchers observe the activity in the lungs and determine the presence of fibrosis or inflammation. Some participants may receive a placebo instead of the active substance. The study aims to improve understanding of PPF and potentially lead to better treatment options in the future.

]]>